레닌-안지오텐신계에 작용하는 항고혈압 약제의 단독요법과 병용요법의 안전성 및 유효성에 대한 체계적 문헌고찰
Systematic Review : Comparative Safety and Efficacy of Monoand Combination Therapy of Anti-hypertensive Agents Acting on the Renin-Angiotensin System
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Given that single blockade with angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin receptor blockers (ARBs)can achieve only partial and undurable suppression of the Renin Angiotensin System (RAS), it has been hypothesized that dual blockage would be more beneficial in the management of blood pressure (BP) reduction and prevention of progressive chronic kidney disease (CKD) than either agent alone. Thus, it has been suggested that the combination of an ACEI and an ARB might provide renal benefits to hypertensive patients over and above BP reduction. However, this might also expose patients to additive or synergistic side effects. We attempted to conduct a systematic review to evaluate the benefits and harms of combination therapy in hypertensive patients with or without kidney diseases. MEDLINE and KoreaMed were searched for relevant randomized clinical trials in adult hypertensive patients with or without diabetes (restricted to 1997,limited to trials published in English). Results were summarized using the random-effects model, and between-studies heterogeneity was estimated with I². A final analysis of ten trials (23,928 patients) revealed that the combination of an ACEI and an ARB reduced blood pressure (SBP/DBP) by 3.95/2.02 mmHg (95% confidence interval [CI], -4.38 to -3.53/-2.33 to -1.71) compared with ACEI monotherapy, and 2.83/2.64 mmHg (95% CI, -3.25 to -2.41/-4.95 to -0.33) compared with ARB monotherapy. Eight trials (391 patients) demonstrated a significant reduction in 24h-proteinuria (weighted mean difference,0.16 g/day, 95% CI, -0.26-0.05), but they did not translate into an improvement in GFR. Tests for heterogeneity showed no difference in effect among the studies. The combination therapy reduced proteinuria by 30% (95% CI, 23% to 37%) and 39% (95% CI, 31% to 48%) compared with ACEI monotherapy and ARB monotherapy, respectively. However, in patients who had proteinuria more than 0.5 g/day, the combination therapy failed to show significant reduction in urinary protein excretion. The current cumulative evidence suggests that diabetic patients with proteinuria on dual RAS blockade have an increase risk of adverse events such as hyperkalemia, hypotension, and so on, compared with ACEI or ARB alone. It is,therefore, proposed that the combination therapy should not be routinely used for the treatment of hypertension with or without compelling indications.
Abstract
Given that single blockade with angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin receptor blockers (ARBs)can achieve only partial and undurable suppression of the Renin Angiotensin System (RAS), it has been hypothesized that dual blockage would be more beneficial in the management of blood pressure (BP) reduction and prevention of progressive chronic kidney disease (CKD) than either agent alone. Thus, it has been suggested that the combination of an ACEI and an ARB might provide renal benefits to hypertensive patients over and above BP reduction. However, this might also expose patients to additive or synergistic side effects. We attempted to conduct a systematic review to evaluate the benefits and harms of combination therapy in hypertensive patients with or without kidney diseases. MEDLINE and KoreaMed were searched for relevant randomized clinical trials in adult hypertensive patients with or without diabetes (restricted to 1997,limited to trials published in English). Results were summarized using the random-effects model, and between-studies heterogeneity was estimated with I². A final analysis of ten trials (23,928 patients) revealed that the combination of an ACEI and an ARB reduced blood pressure (SBP/DBP) by 3.95/2.02 mmHg (95% confidence interval [CI], -4.38 to -3.53/-2.33 to -1.71) compared with ACEI monotherapy, and 2.83/2.64 mmHg (95% CI, -3.25 to -2.41/-4.95 to -0.33) compared with ARB monotherapy. Eight trials (391 patients) demonstrated a significant reduction in 24h-proteinuria (weighted mean difference,0.16 g/day, 95% CI, -0.26-0.05), but they did not translate into an improvement in GFR. Tests for heterogeneity showed no difference in effect among the studies. The combination therapy reduced proteinuria by 30% (95% CI, 23% to 37%) and 39% (95% CI, 31% to 48%) compared with ACEI monotherapy and ARB monotherapy, respectively. However, in patients who had proteinuria more than 0.5 g/day, the combination therapy failed to show significant reduction in urinary protein excretion. The current cumulative evidence suggests that diabetic patients with proteinuria on dual RAS blockade have an increase risk of adverse events such as hyperkalemia, hypotension, and so on, compared with ACEI or ARB alone. It is,therefore, proposed that the combination therapy should not be routinely used for the treatment of hypertension with or without compelling indications.
참고문헌 (41)
- Chobanian AV, "Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure", Hypertension, 42(6), pp.1206~1252 (2003)
- Vasan RS, "Impact of highnormal blood pressure on the risk of cardiovascular disease", N Engl J Med, 345, pp.1291~1297 (2001)
- Mancia G, "ESHESC Practice Guidelines for the Management of Arterial Hypertension: ESH-ESC Task Force on the Management of Arterial Hypertension", J Hypertens, 25(9), pp.1751~1762 (2007)
- Ogihara T, "The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2009)", Hypertension Research, 32(1), pp.3~107 (2009)
- 성예나, "고혈압 환자의 혈압강하제 처방양상- 외래 처방전을 중심으로", 한국임상약학회지, 19(2), pp.167~179 (2009), 한국임상약학회
- Steven A, "The rennin-angiotensin aldosterone system: Pathophysiological role and pharmacologic inhibition", J Manag Care Pharm, 13(8), pp.S9~S20 (2007)
- Jafar TH, "Progression of chronic kidney disease: the role of blood pressure control, proteinuria, and angiotensin-converting enzyme inhibition: a patient-level meta-analysis", Ann Intern Med, 139, pp.244~252 (2003)
- Messerli FH, "Dogma disputed: can aggressively lowering blood pressure in hypertensive patients with coronary disease be dangerous", Ann Intern Med, 144, pp.884~893 (2006)
- Doulton TW, "Systematic review of combined angiotensin-converting enzyme inhibition and angiotensin receptor blockade in hypertension", Hypertension, 45(5), pp.880~886 (2005)
- Choi KE, "Analysis of outpatient claims containing more than 13 drugs per prescription -focusing on antihypertensive agents-", ~ (2008)
- The ONTARGET Investigators, "Telmisartan, ramipril, or both in patients at high risk for vascular events", NEW ENGLAND JOURNAL OF MEDICINE, 358(15), pp.1547~1559, MASSACHUSETTS MEDICAL SOC
- Agarwal R, "Add-on angiotensin receptor blockade with maximized ACE inhibition", Kidney Int, 59, pp.2282~2289 (2001)
- Azizi M, "Pilot study of combined blockade of the renin-angiotensin system in essential hypertensive patients", J Hypertens, 18, pp.1139~1147 (2000)
- Ferrari P, "Additive anti-proteinuric effect of combined ACE inhibition and angiotensin II receptor blockade", J Hypertens, 20, pp.125~130 (2002)
- Morgan T, "Effect of candesartan alone and in combination on blood pressure and microalbuminuria", J Renin Angiotensin Aldosterone Syst, 5, pp.64~71 (2004)
- Stergiou GS, "Additive hypotensive effect of angiotensin-converting enzyme inhibition and angiotensin-receptor antagonism in essential hypertension", J Cardiovasc Pharmacol, 5, pp.937~941 (2000)
- Weir MR, "Valsartan alone or with a diuretic or ACE inhibitor as treatment for African American hypertensives: relation to salt intake", Am J Hypertens, 14, pp.665~671 (2001)
- Moon-JaeKim, "Additive Antiproteinuric Effect of Combination Therapy with ACE Inhibitor and Angiotensin II Receptor Antagonist: Differential Short-term Response between IgA Nephropathy and Diabetic Nephropathy", Yonsei Medical Journal, 44(3), pp.463~472 (2003), 연세대학교의과대학
- Luno J, "Effects of dual blockade of the renin-angiotensin system in primary proteinuric nephropathies", Kidney Int, 62(82), pp.47~52 (2002)
- Fujisawa T, "Combination of halfdoses of angiotensin type 1 receptor antagonist and angiotensin-converting enzyme inhibitor in diabetic nephropathy", Am J Hypertension, 18, pp.13~17 (2005)
- Nakao N, "Combination treatment of angiotensin-II receptor blocker and angiotensinconverting- enzyme inhibitor in non-diabetic renal disease(COOPERATE): a randomised controlled trial", Lancet, 61, pp.117~124 (2003)
- Berger ED, "Reduction of proteinuria; combined effects of receptor blockade and low dose angiotensin-converting enzyme inhibition", J Hypertens, 20, pp.739~743 (2002)
- Menne J, "Valsartan in combination with lisinopril versus the respective high dose monotherapies in hypertensive patients with microalbuminuria: the VALERIA trial", J Hypertens, 26, pp.1860~1867 (2008)
- Jacobsen P, "Dual blockade of the renin-angiotensin system in type 1 patients with diabetic nephropathy", Nephrol Dial Transplant, 17, pp.1019~1024 (2002)
- Jacobsen P, "Additive effect of ACE inhibition and angiotensin II receptor blockade in type 1 diabetic patients with diabetic nephropathy", J Am Soc Nephrol, 14, pp.992~999 (2003)
- Jacobsen P, "Dual blockade of the renin-angiotensin system vs maximal recommended dose of ACE inhibition in diabetic nephropathy", Kidney Int, 63, pp.1874~1880 (2003)
- Rossing K, "Dual blockade of the renin-angiotensin system in diabetic nephropathy. A randomized double-blind cross-over study", Diabetes Care, 25, pp.95~100 (2002)
- Rossing K, "Renoprotective effects of adding angiotensin II receptor blocker to maximal recommended doses of ACE inhibitor in diabetic nephropathy", Diabetes Care, 26, pp.2268~2274 (2003)
- Mogensen CE, "Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and noninsulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study", BMJ, 21, pp.1440~1444 (2000)
- Andersen NH, "Long-term dual blockade with candesartan and lisinopril in hypertensive patients with diabetes : the CALMⅡstudy", Diabetes Care, 28, pp.279~287 (2005)
- Mann JF, "ONTARGET investigators. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomized, double-blind, controlled trial", Lancet, 372, pp.547~553 (2008)
- Brenner DM, "Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy", N Engl J Med, 345, pp.861~869 (2001)
- Fisman EZ, "Losartan and diabetic nephropathy: commentaries on the RENAAL study", Cardiovasc Diabetol, 8, pp.1~2 (2002)
- The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia), "Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy", Lancet, 349(9069), pp.1857~1863 (1997)
- MacKinnon M, "and an ACE inhibitor in proteinuric renal disease: a systematic review of the efficacy and safety data", Am J Kidney Dis, 48(1), pp.8~20 (2006)
- Maschio G, "Effects of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. The Angiotensin- Converting-Enzyme inhibition in Progressive Renal Insufficiency Study Group", N Engl J Med, 334, pp.939~945 (1996)
- "K", DOQI Clinical practice guidelines for peritoneal dialysis adequacy, 2006, pp.48(1), 129~
- "VALID Trial"[URL]
- McAlister FA, "The safety of combining angiotensin-converting-enzyme inhibitors with angiotensin-receptor blockers in elderly patients: a population-based longitudinal analysis", CMAJ, 183(6), pp.655~662 (2011)
- "2011 CHEP Recommendations for the management of hypertension"[URL]